Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors

NCT05845671 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05845671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05845671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 17, 2023
Completion date
January 31, 2028
Enrollment
12 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer